Vacunacionadultos

Greenwich LifeSciences, Inc. to Participate at Texas Life Sciences Forum Investor Conference

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that it was selected to present at the 2020 Texas Life Science Forum conference to be held virtually from November 10-12, 2020.

Snehal Patel, CEO of Greenwich LifeSciences, will present and will be available to participate in one-on-one meetings with members of the investor community who are registered to attend the conference. The presentation will be held between approximately 12:00-12:50 pm EST on November 10, 2020, and will highlight the Company’s GP2 program and its plans to commence a Phase III clinical trial. The presentation will be followed by a question and answer session from a 3 member panel of investors. The Company will also participate in a showcase event between approximately 4:30-5:00 pm EST on the

Read More